|
|
 |
|
Viewing report
|
|
|
|
Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec
Decision Resources, Inc., Aug 2009, Pages: 22
Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial revenues. Despite recent advances in the treatment of this disease (most notably, targeted therapeutics such as Novartis’s Gleevec/Glivec [imatinib]), significant unmet needs remain because certain segments of the CML patient population are intolerant of or become resistant to existing therapies. Emerging therapies that focus on the unmet needs of current therapeutics have a good chance of replicating Gleevec’s success.
Questions Answered in This Report
Properly diagnosing CML is an integral part of choosing an effective treatment.
- How is CML diagnosed?
- What role does genetic testing play in developing and deploying drugs for CML?
- What are the symptoms of CML?
Treatment options for CML are more targeted today than in recent history.
- How was CML previously treated?
- Why have targeted therapies proved to be better CML treatment options?
Despite treatment advances, opportunities remain for emerging CML agents.
- What are these opportunities?
- Are the opportunities potentially lucrative enough to motivate drug developers?
Scope
- Disease overview: disease causes and indicators, physical and genetic symptoms, diagnosis, classification, epidemiology, and disease progression.
- Current CML therapies: chemotherapy, interferon-alpha, targeted therapies, stem cell therapy.
- Emerging CML therapies: targeted therapies, therapies focused on particular disease mutations.
- Market outlook: 2008 CML market sales, opportunities for current and emerging CML therapies.
Customers who bought this item also bought
Acute Lymphocytic Leukemia - Unmet Needs in Adult and Pediatric Populations Drive Recent Market Developments
Chronic Myelogenous Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Can New Therapies Unseat Traditional Chemotherapy Regimens in Acute Myelogenous Leukemia?
Pipeline Insight: Leukemias Underserved patient populations offer potential for market growth
Chronic Myelocytic Leukemia (CML) - Pipeline Review, Q1 2011
Chronic Myelocytic Leukemia (CML) - Pipeline Review, H2 2011
Chronic Myelocytic Leukemia (CML) - Pipeline Review, Q4 2010
Leukemias: Principles and Practice of Therapy
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2012
Biomarker and Diagnostic Opportunities Associated with Targeted Cancer Therapies
|
|
|
|
